Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
TScan Therapeutics, Inc. (TCRX) had Consolidated Net Income/Loss of $-30.36M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$1.05M |
|
$-30.36M |
|
-- |
|
$1.05M |
|
$31.54M |
|
$-30.49M |
|
$0.13M |
|
$-30.36M |
|
$-30.36M |
|
$-30.36M |
|
$-30.36M |
|
|
Consolidated Net Income/Loss |
$-30.36M |
$-30.36M |
|
$-30.49M |
|
$-29.79M |
|
129.95M |
|
129.95M |
|
$-0.23 |
|
$-0.23 |
|
| Balance Sheet Financials | |
$104.40M |
|
$7.74M |
|
$67.05M |
|
$171.45M |
|
$30.96M |
|
$21.07M |
|
$71.47M |
|
$102.43M |
|
$69.02M |
|
$69.02M |
|
$69.02M |
|
67.78M |
|
| Cash Flow Statement Financials | |
$-51.81M |
|
$-0.54M |
|
$0.10M |
|
$157.44M |
|
$105.19M |
|
$-52.25M |
|
$4.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.37 |
|
-- |
|
-- |
|
0.23 |
|
0.47 |
|
100.00% |
|
-2901.33% |
|
-2901.33% |
|
-- |
|
-2888.58% |
|
-2888.58% |
|
$-52.35M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-43.99% |
|
-43.99% |
|
-17.71% |
|
-33.70% |
|
$1.02 |
|
$-0.40 |
|
$-0.40 |
|